Search results for "Lymphoma"

showing 10 items of 707 documents

Production of rosmarinic acid and salvianolic acid B from callus culture of Salvia miltiorrhiza with cytotoxicity towards acute lymphoblastic leukemi…

2016

Salvia miltiorrhiza (SM) Bunge is one of the widely-used Chinese medicinal herbs. In this study, the chemical constituents and anticancer potential of SM stems and leaves were examined with those of respective callus cultures. The callus culture for stem and leaf explants was initiated in modified Murashige and Skoog (MS) medium. Active constituents of respective extracts were analyzed by high performance liquid chromatography coupled with DAD and MS (HPLC-DAD-MS). Rosmarinic acid (RA) and salvianolic acid B (Sal B) were determined to be the main phenolic compounds. Quantitative analyses revealed that callus stem extracts produced higher amount of RA and Sal B (stem RA: 1.27±0.38%; stem Sal…

0106 biological sciences0301 basic medicineSalvia miltiorrhizaBiology01 natural sciencesHigh-performance liquid chromatographySalvia miltiorrhizaDepsidesAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundCytotoxicityIC50Chromatography High Pressure LiquidBenzofuransTraditional medicinePlant ExtractsRosmarinic acidfungifood and beveragesGeneral MedicinePrecursor Cell Lymphoblastic Leukemia-LymphomaIn vitroPlant Leaves030104 developmental biologyBiochemistrychemistryCinnamatesCallus010606 plant biology & botanyFood ScienceExplant cultureDrugs Chinese HerbalFood chemistry
researchProduct

New Acyclic Cytotoxic Jasplakinolide Derivative from the Marine Sponge Jaspis splendens

2019

A new acylic jasplakinolide congener (2), another acyclic derivative requiring revision (4), together with two jasplakinolide derivatives including the parent compound jasplakinolide (1) were isolated from the Indonesian marine sponge Jaspis splendens. The chemical structures of the new and known compounds were unambiguously elucidated based on HRESIMS and exhaustive 1D and 2D NMR spectral analysis as well as a comparison of their NMR data with those of jasplakinolide (1). The isolated jasplakinolides inhibited the growth of mouse lymphoma (L5178Y) cells in vitro with IC50 values in the low micromolar to nanomolar range.

0106 biological sciencesStereochemistryPharmaceutical Science01 natural sciencesjasplakinolide Z<sub>5</sub>Drug Discovery<i>Jaspis splendens</i>Ic50 valuesCytotoxic T cellSpectral analysisPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5cytotoxic activitybiology010405 organic chemistryChemistry010604 marine biology & hydrobiologyMouse LymphomaJaspis splendensbiology.organism_classificationIn vitro0104 chemical sciencesSpongelcsh:Biology (General)Two-dimensional nuclear magnetic resonance spectroscopyjasplakinolide Z<sub>6</sub>Marine Drugs
researchProduct

Indicaxanthin from Opuntia Ficus Indica (L. Mill) impairs melanoma cell proliferation, invasiveness, and tumor progression.

2018

Abstract Background: A strong, reciprocal crosstalk between inflammation and melanoma has rigorously been demonstrated in recent years, showing how crucial is a pro-inflammatory microenvironment to drive therapy resistance and metastasis. Purpose: We investigated on the effects of Indicaxanthin, a novel, anti-inflammatory and bioavailable phytochemical from Opuntia Ficus Indica fruits, against human melanoma both in vitro and in vivo. Study Design and Methods: The effects of indicaxanthin were evaluated against the proliferation of A375 human melanoma cell line and in a mice model of cutaneous melanoma. Cell proliferation was assessed by MTT assay, apoptosis by Annexin V-Fluorescein Isothio…

0301 basic medicine3003MaleSkin NeoplasmsPyridinesPyridinePhytochemicalsMelanoma ExperimentalPharmaceutical ScienceIndicaxanthinApoptosisBcl-2 B cell lymphoma gene-2 (Bcl-2)chemistry.chemical_compoundMice0302 clinical medicineOpuntia Ficus Indica (L.Mill)Settore BIO/10 - BiochimicaDrug DiscoveryCXCL1 chemokine (C-X-C motif) ligand 1MelanomaNF-κB nuclear factor kappa BMTT 3-[45-dimethyltiazol-2-yl]-25-diphenyl tetrazolium bromideMelanomaNF-kappa BOpuntiaComplementary and Alternative Medicine2708 DermatologyBetaxanthinsCXCL1030220 oncology & carcinogenesisMolecular MedicinePhC phytochemicalGrowth inhibitionIndicaxanthinHumanBiologyPhytochemicalNHEM normal human epidermal melanocyte03 medical and health sciencesc-FLIP FLICE-inhibitory proteinIn vivoCell Line TumormedicineAnimalsHumansNeoplasm InvasivenessSkin NeoplasmCell ProliferationNeoplasm InvasiveneInflammationPharmacologyCell growthAnimalDrug Discovery3003 Pharmaceutical ScienceApoptosimedicine.diseaseMice Inbred C57BL030104 developmental biologyComplementary and alternative medicinechemistryTumor progressionList of Abbrevations: AxV-FITC annexin V-fluorescein isothiocyanateBetaxanthinFruitCutaneous melanomaCancer researchPI propidium iodide PIPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Analysis of nucleophosmin–anaplastic lymphoma kinase (NPM‐ALK)‐reactive CD8+ T cell responses in children with NPM‐ALK+ anaplastic large cell lymphoma

2016

Summary Cellular immune responses against the oncoantigen anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) have been detected using peptide-based approaches in individuals preselected for human leucocyte antigen (HLA)-A*02:01. In this study, we aimed to evaluate nucleophosmin (NPM)-ALK-specific CD8+ T cell responses in ALCL patients ensuring endogenous peptide processing of ALK antigens and avoiding HLA preselection. We also examined the HLA class I restriction of ALK-specific CD8+ T cells. Autologous dendritic cells (DCs) transfected with in-vitro-transcribed RNA (IVT-RNA) encoding NPM–ALK were used as antigen-presenting cells for T cell …

0301 basic medicineAdolescentT cellImmunologyHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesLymphocyte ActivationAntibodiesCell Line03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmT-Lymphocyte Subsetshemic and lymphatic diseasesmedicineImmunology and AllergyAnaplastic lymphoma kinaseCytotoxic T cellAnimalsHumansChildAnaplastic large-cell lymphomaAllelesintegumentary systemELISPOTHistocompatibility Antigens Class IInfantOriginal ArticlesProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologymedicine.anatomical_structureChild PreschoolImmunologyCancer researchLymphoma Large-Cell AnaplasticCD8030215 immunology
researchProduct

Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas

2015

Burkitt lymphoma (BL) is an aggressive neoplasm characterized by consistent morphology and phenotype, typical clinical behavior and distinctive molecular profile. The latter is mostly driven by the MYC over-expression associated with the characteristic translocation (8;14) (q24; q32) or with variant lesions. Additional genetic events can contribute to Burkitt Lymphoma pathobiology and retain clinical significance. A pathogenetic role for Epstein-Barr virus infection in Burkitt lymphomagenesis has been suggested; however, the exact function of the virus is largely unknown. In this study, we investigated the molecular profiles (genes and microRNAs) of Epstein-Barr virus-positive and -negative…

0301 basic medicineBART6; Burkitt lymphoma; EBV; miRNA; pathogenesisEpstein-Barr Virus InfectionsHerpesvirus 4 HumanpathogenesiRNA-binding proteinRNA-Binding ProteinEpstein-Barr Virus Infectionhemic and lymphatic diseasesCluster AnalysisViralOligonucleotide Array Sequence AnalysisGeneticsBART6; Burkitt lymphoma; EBV; miRNA; pathogenesis; Burkitt Lymphoma; Cluster Analysis; Cytoskeletal Proteins; Epstein-Barr Virus Infections; Gene Expression Profiling; Gene Expression Regulation Neoplastic; Gene Expression Regulation Viral; Herpesvirus 4 Human; Host-Pathogen Interactions; Humans; Immunohistochemistry; MicroRNAs; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Phospholipase C delta; RNA Viral; RNA-Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction; ras Proteins; OncologyReverse Transcriptase Polymerase Chain ReactionpathogenesisMicrofilament ProteinsIntracellular Signaling Peptides and ProteinsBurkitt lymphomaRNA-Binding ProteinsMicroRNAPhenotypeImmunohistochemistryNeoplasm ProteinsHost-Pathogen InteractionGene Expression Regulation NeoplasticOncologyHost-Pathogen InteractionsRNA ViralHumanResearch PaperGene Expression Regulation ViralBART6BiologySettore MED/08 - Anatomia PatologicaVirusNeoplasm Protein03 medical and health sciencesEBVmicroRNACytoskeletal ProteinmedicineHumansEpstein–Barr virus infectionGenemiRNANeoplasticCluster AnalysiOligonucleotide Array Sequence AnalysiGene Expression ProfilingHerpesvirus 4ras Proteinmedicine.diseaseLymphomaGene expression profilingCytoskeletal ProteinsMicroRNAs030104 developmental biologyGene Expression Regulationras ProteinsRNABART6; EBV; burkitt lymphoma; miRNA; pathogenesisPhospholipase C deltaOncotarget
researchProduct

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreat…

2018

Abstract Introduction: Immunochemotherapy is standard of care treatment for previously untreated patients (pts) with advanced stage follicular lymphoma (FL). However, the majority of pts relapse, with around 20% relapsing within 2 years. Obinutuzumab (GA101; G) is a glycoengineered type II anti-CD20 monoclonal antibody (mAb) with increased antibody-dependent cell-mediated phagocytosis and cytotoxicity, and direct B-cell killing, compared with the type I mAb rituximab (R). The randomized Phase III GALLIUM study (NCT01332968) compared the efficacy and safety of G-chemotherapy (G-chemo) vs R-chemotherapy (R-chemo) in previously untreated pts with advanced stage FL. In the primary analysis (PA)…

0301 basic medicineBendamustinemedicine.medical_specialtyImmunologyFollicular lymphomaLower riskBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineMedicineIn patientProgression-free survivalbusiness.industryCell BiologyHematologymedicine.diseaseLymphomaDiscontinuation030104 developmental biologychemistry030220 oncology & carcinogenesisbusinessmedicine.drugBlood
researchProduct

Checkpoint Inhibition in Non-Hodgkin's Lymphoma.

2017

As patients continue to die from malignant lymphoma, novel treatment options continue to be warranted. To successfully grow and spread, tumor cells need to escape the immune system; therefore, the augmentation or restoration of immune effectors against the malignant cell could be of great value, as shown, e.g., for allogeneic transplantation. A deepened understanding of the regulation of activation and inhibition of the T cell-based effector mechanisms has led to the development of drugs that are able to modify specific checkpoints of this system and thereby raise an immune response against tumor cells. With dramatic responses observed in Hodgkin's disease (HD), interest has risen to explor…

0301 basic medicineCancer ResearchAllogeneic transplantationT cellT-LymphocytesAntineoplastic AgentsDisease03 medical and health sciences0302 clinical medicineImmune systemhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineEffectorbusiness.industryLymphoma Non-HodgkinAntibodies MonoclonalHematologymedicine.diseaseIpilimumabLymphomaNon-Hodgkin's lymphoma030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisCancer researchTumor EscapePrimary mediastinal B-cell lymphomabusinessRituximabOncology research and treatment
researchProduct

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

2021

Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next‐generation sequencing (NGS) upon disease progression. We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK‐positive NSCLC patients at disease progression to an ALK‐I. These samples were analyzed by NGS and digital PCR. A tool to retrieve variants at the ALK locus was developed (VALK tool). We identified at least one resistance mutation in the ALK locus in ten (38.5%) p…

0301 basic medicineCancer ResearchLung NeoplasmsEML4-ALKAntineoplastic AgentsEML4‐ALKmedicine.disease_causeNSCLCIDH2Circulating Tumor DNA03 medical and health sciencesALK-TKI0302 clinical medicineCarcinoma Non-Small-Cell LungMAP2K1hemic and lymphatic diseasesALK‐TKIGeneticsmedicineHumansAnaplastic lymphoma kinaseAnaplastic Lymphoma KinaseDigital polymerase chain reactionPrecision MedicineLiquid biopsyProtein Kinase InhibitorsneoplasmsResearch ArticlesRC254-282MutationCrizotinibliquid biopsybusiness.industryHigh-Throughput Nucleotide SequencingNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineResistance mutation3. Good health030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisNGSMutationCancer researchMolecular MedicinebusinessResearch Articlemedicine.drugMolecular Oncology
researchProduct

Constitutive psgl-1 correlates with cd30 and tcr pathways and represents a potential target for immunotherapy in anaplastic large t-cell lymphoma

2021

Simple Summary P-selectin glycoprotein ligand-1 (PSGL-1), coded by the SELPLG gene, is the major ligand of selectins and plays a pivotal role in tethering, rolling and extravasation of immune cells. PSGL-1 involvement in core molecular programs, such as SYK, PLCγ2, PI3Kγ or MAPK pathways, suggests additional functions beyond the modulation of cell trafficking. Recently, several studies identified a novel mechanism responsible for PSGL-1-mediated immune suppression in the tumor microenvironment and proved a novel concept of PSGL-1 as a critical checkpoint molecule for tumor immunotherapy. The immunotherapeutic approach has gained an ever-growing interest in the treatment of several hematolog…

0301 basic medicineCancer ResearchPTCLCD30medicine.medical_treatmentSykLymphoproliferative disordersBiologyALCL; ALK; CD30; Immunotherapy; PSGL-1; PTCL; TCRArticle03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesmedicineT-cell lymphomaPSGL-1RC254-282integumentary systemT-cell receptorNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseaseALCLLymphomaGene expression profiling030104 developmental biologyOncologyALK030220 oncology & carcinogenesisCD30Cancer researchImmunotherapyTCR
researchProduct

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique

2016

Abstract Patients with malignant gliomas have a poor prognosis with average survival of less than one year. Whereas in other tumor entities the characteristics of tumor metabolism are successfully used for therapeutic approaches, such developments are very rare in brain tumors, notably in gliomas. One metabolic feature characteristic of gliomas, in particular diffuse astrocytomas and oligodendroglial tumors, is the variable content of D-2-hydroxyglutarate (D2HG), a metabolite, which was discovered first in this tumor entity. D2HG is generated in large amounts due to various “gain-of–function” mutations in the isocitrate dehydrogenases IDH-1 and IDH-2. Meanwhile, D2HG has been detected in se…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyMetabolite610 MedizinBiology03 medical and health scienceschemistry.chemical_compoundmedicineBioluminescence imagingBioluminescenceOligodendroglial TumorOriginal Researchddc:610D-2 hydroxyglutarateglioblastomaMyeloid leukemiaCancerACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; IDH2 MUTATIONS; CHROMATOGRAPHY/MASS SPECTROMETRY; MAGNETIC-RESONANCE; 2-HYDROXYGLUTARATE; CANCER; GLIOMAS; L-2-HYDROXYGLUTARATE; METABOLITES; D-2 hydroxyglutarate; IDH mutations; bioluminescence imaging; oncometabolite; glioblastomabioluminescence imagingIDH mutationsmedicine.diseaseoncometaboliteLymphoma030104 developmental biologychemistryOncologyChondrosarcoma
researchProduct